Literature DB >> 6765955

Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes.

G E Staal, J W Stoop, B J Zegers, L H Siegenbeek van Heukelom, M J van der Vlist, S K Wadman, D W Martin.   

Abstract

Purine nucleoside phosphorylase deficiency is associated with a severely defective T-cell immunity. A patient with purine nucleoside phosphorylase deficiency was treated with transfusions of irradiated erythrocytes and plasma. This resulted in a remarkable correction of the metabolic disturbances in the patient. The urinary excretion of inosine, deoxyinosine, guanosine, and deoxyguanosine decreased, whereas uric acid excretion as well as serum uric acid concentration increased. It could be shown that the enzyme activity of the circulating erythrocytes correlated inversely with the urinary excretion of nucleosides and directly with the excretion of uric acid. As a consequence of the therapy, several glycolytic intermediates of the erythrocytes were increased, especially 2,3-diphosphoglycerate. The high 2,3-diphosphoglycerate level caused a shift to the right of the oxygen dissociation curve (P50 = 32.9 mm Hg). The immunological status of the patient showed definite improvement after the enzyme replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6765955      PMCID: PMC371344          DOI: 10.1172/JCI109639

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Selective severe cellular immunodeficiency. Effect of thymus transplantation and transfer factor administration.

Authors:  J W Stoop; V P Eijsvoogel; B J Zegers; B Blok-Schut; D W van Bekkum; R E Ballieux
Journal:  Clin Immunol Immunopathol       Date:  1976-11

2.  2,3-diphosphoglycerate affects enzymes of glucose metabolism in red blood cells.

Authors:  E Beutler
Journal:  Nat New Biol       Date:  1971-07-07

3.  Studies on erythrocyte glycolysis. I. Determination of the glycolytic intermediates in human erythrocytes.

Authors:  S Minakami; C Suzuki; T Saito; H Yoshikawa
Journal:  J Biochem       Date:  1965-12       Impact factor: 3.387

4.  Purines: supply by liver to tissues.

Authors:  J B Pritchard; F Chavez-Peon; R D Berlin
Journal:  Am J Physiol       Date:  1970-11

5.  An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunity.

Authors:  L H van Heukelom; G E Staal; J W Stoop; B J Zegers
Journal:  Clin Chim Acta       Date:  1976-10-01       Impact factor: 3.786

6.  Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase.

Authors:  A Cohen; D Doyle; D W Martin; A J Ammann
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

7.  Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  S H Polmar; R C Stern; A L Schwartz; E M Wetzler; P A Chase; R Hirschhorn
Journal:  N Engl J Med       Date:  1976-12-09       Impact factor: 91.245

8.  Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency.

Authors:  J W Stoop; B J Zegers; G F Hendrickx; L H van Heukelom; G E Staal; P K de Bree; S K Wadman; R E Ballieux
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

9.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

10.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

View more
  9 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Adenosine deaminase and purine nucleoside phosphorylase deficiencies: evaluation of therapeutic interventions in eight patients.

Authors:  M L Markert; M S Hershfield; R I Schiff; R H Buckley
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

3.  Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Dushyant Verma; Susan O'Brien; John Michael Kilpatrick; Yuling Chen; Brenita F Tyler; Susan Bickel; Shanta Bantia; Michael J Keating; Hagop Kantarjian; Varsha Gandhi; Farhad Ravandi
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

4.  Purine deoxynucleosides and adenosine dialdehyde decrease 5-amino-4-imidazolecarboxamide (Z-base)-dependent purine nucleotide synthesis in cultured T and B lymphoblasts.

Authors:  G R Boss
Journal:  Biochem J       Date:  1987-03-01       Impact factor: 3.857

5.  Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.

Authors:  G A Kicska; L Long; H Hörig; C Fairchild; P C Tyler; R H Furneaux; V L Schramm; H L Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

6.  Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans.

Authors:  W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine.

Authors:  G R Boss; R B Pilz
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

8.  Upfront Enzyme Replacement via Erythrocyte Transfusions for PNP Deficiency.

Authors:  Anna Eichinger; Horst von Bernuth; Michael H Albert; Fabian Hauck; Cinzia Dedieu; Sebastian A Schroeder; Giancarlo la Marca
Journal:  J Clin Immunol       Date:  2021-02-27       Impact factor: 8.317

9.  5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.

Authors:  Shamim I Ahmad
Journal:  Med Hypotheses       Date:  2020-04-22       Impact factor: 1.538

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.